A new drug moxifloxacine (avelox®, "Bayer", Germany): experience in the treatment of urological diseases
- Autores: Derevyanko II1
-
Afiliações:
- Edição: Nº 3 (2003)
- Páginas: 24-26
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/274908
- ID: 274908
Citar
Texto integral
Resumo
Fluoroquinolones (ciprofloxacine, ofloxacin, pefloxacin, lomefloxacin, etc.) have a long and cussessful history of application in the treatment of urinary infection. They are the first-line drugs in the above nosological entity. Fluoroquinolones of a new generation including moxifloxacin demonstrate a wider spectrum of antimicrobial activity, updated pharmacokinetic properties, low resistance that is are promising in the treatment of urinary infection. We tried moxifloxacin in the treatment of both complicated and uncomplicated infections of the urinary tracts. The response reached 95.7%, bacteriological effectiveness 85.7%. The drug is well tolerated, side effects were not observed. Thus, moxifloxacin can be used in the treatment of urinary and urogenital infections.
Bibliografia
- Падейская Е. Н., Яковлев В. П. Антимикробные препараты группы фторхинолонов в клинической практике. М.: Логата; 1998.
- Яковлев В. П., Яковлев С. В. Моксифлоксацин. М.; 2002.
- MacGowan A. P. Moxifloxacin (BAY 12-8039): a new methoxyquinolone antibacterial. Exp. Opin.Invest. Drugs 1999; 8 (2): 181-199.
- Bebear С. М., Renaudin H. et al. In vitro activity of BAY 128039 a new fluoroquinolone against mycoplasmas. Antimicrob. Agents Chemother. 1998; 42: 703-704.
- Roblin P. M., Hammerschlag M. R. In vitro activity of a new 8metoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Ibid. 951-952.
- Ullman U., Krausse R., Schulbert S. Moxifloxacin: comparative in vitro activity against Ureaplasma urealiticum and Mycoplasma hominis. Ibid. 1999; 44 (suppl. A); abstr. N 476.
Arquivos suplementares
